Epithelial-to-Mesenchymal Transition Supports Ovarian Carcinosarcoma Tumorigenesis and Confers Sensitivity to Microtubule Targeting with Eribulin

Grants

Funding Acknowledgements

This work was supported by fellowships and grants from the National Health and Medical Research Council (NHMRC Australia; project grants 1062702, 1081178 to C.L. Scott, and 1104348 to M.J. Wakefield, D.D. Bowtell, A.T. Papenfuss, and C.L. Scott, Senior Research Fellowship 1116955 (to A.T. Papenfuss), Investigator grant 2008692 (to J.E. Vince), Ideas grant 1183070 (to J.E. Vince); the Stafford Fox Medical Research Foundation (to E.L. Kyran, J. Bedo, C.J. Vandenberg, R. Lim, A.T. Papenfuss, C.L. Scott, and H.E. Barker); the Lorenzo and Pamela Galli Medical Research Trust (to A.T. Papenfuss); Cancer Council Victoria (Sir Edward Dunlop Fellowship in Cancer Research to C.L. Scott and Grant-in-Aid (1186314) jointly funded with the Ovarian Cancer Research Foundation to G. Ratnayake, C.J. Vandenberg, A. Farrell, and H.E. Barker); the Victorian Cancer Agency (Clinical Fellowships CRF10-20, CRF16014 to C.L. Scott and Early Career Research Fellowship ECRF19003 to G. Dall); Herman Trust University of Melbourne (to C.L. Scott); CRC Cancer Therapeutics (grant support to C.L. Scott and PhD top-up scholarship to G.Y. Ho); Australian Commonwealth Government and the University of Melbourne (Research Training Program Scholarship to G.Y. Ho and A. Hadla); Cancer Research UK Cambridge Institute Studentship; Cambridge Poynton Scholarship; Cambridge Trust International Scholarship (PhD funding for E.L. Kyran); research funding from Eisai (to C.L. Scott and H.E. Barker). The Scottish Genomes Partnership is funded by the Chief Scientist Office of the Scottish Government Health Directorates (grant reference SGP/1) and The Medical Research Council Whole Genome Sequencing for Health and Wealth Initiative. Additional funding was provided by the Medical Research Council (the Glasgow Molecular Pathology Node, grant reference MR/N005813/1), Cancer Research UK (grant references A15973 to I.A. McNeish and A17263 to A.V. Biankin), the Wellcome Trust (grant reference 103721/Z/14/Z to A.V. Biankin), and the Beatson Cancer Charity (grant reference 15-16-051 to I.A. McNeish and P. Roxburgh), the Imperial NIHR Biomedical Research Centre (grant references PSC593 and P77646 to I.A. McNeish, D.P. Ennis, and Hasan B. Mirza), and Ovarian Cancer Action (grant reference P76567 to I.A. McNeish, D.P. Ennis, and Hasan B. Mirza). The authors thank Silvia Stoev, Rachel Hancock, and Kathy Barber for technical assistance. They thank Profs. Ronny Drapkin and Jane Visvader and Osaka Bioscience Institute, Japan, and Prof. Johannes H. Schulte for kind gifts of the mouse strains used to generate the GEMM. The authors thank Dr. P. Haluska (Mayo Clinic) for the cryopreserved PDX material used to re-establish PDXs PH419, PH142, PH006, PH003, and PH592 within their laboratory. They thank Eisai Co., Ltd., for supply of eribulin. The authors thank Prof. Elizabeth Swisher and Dr. M. Radke for the BROCA sequencing of case #1040, Prof. Sean Grimmond and Dr. J. Vissers for WGS of cases #1105 and #1177, and Andrew Fellowes for the TSO500 sequencing of cases PH142, PH003, and PH006. They thank Jocelyn Penington for data deposition to EGA. This work was made possible through the Australian Cancer Research Foundation, the Victorian State Government Operational Infrastructure Support, and Australian Government NHMRC IRIISS. The Australian Ovarian Cancer Study Group was supported by the U.S. Army Medical Research and Materiel Command under DAMD17-01-1-0729, The Cancer Council Victoria, Queensland Cancer Fund, The Cancer Council New South Wales, The Cancer Council South Australia, The Cancer Council Tasmania and The Cancer Foundation of Western Australia (Multi-State Applications 191, 211, and 182), and the National Health and Medical Research Council of Australia (NHMRC; ID199600, ID400413, and ID400281). The Australian Ovarian Cancer Study gratefully acknowledges additional support from Ovarian Cancer Australia and the Peter MacCallum Foundation. The AOCS also acknowledges the cooperation of the participating institutions in Australia and acknowledges the contribution of the study nurses, research assistants, and all clinical and scientific collaborators to the study. The complete AOCS Study Group can be found at www.aocstudy.org. Support was also provided by Ovarian Cancer Action, the Cancer Research UK Centres and Experimental Cancer Medicine Centres at both Glasgow and Imperial and the NIHR Imperial Biomedical Research Centre. The authors would like to thank all of the women who participated in these research programs.